Diabetes
Is tirzepatide linked to fewer deaths than GLP-1 drugs?
Open access · cc by · source: Europe PMC
In 140,308 US adults with type 2 diabetes, tirzepatide was associated with lower all-cause mortality (AHR 0.58) and fewer major cardiovascular and kidney events than GLP-1 receptor agonists.
Study at a glance
- Design
- Cohort — Retrospective TriNetX cohort of US adults with type 2 diabetes initiating tirzepatide vs GLP-1 RA (June 2022–June 2023), with 1:1 propensity-score matching
- N
- N=140308 · 140,308 patients: 14,834 tirzepatide and 125,474 GLP-1 RA before matching; median follow-up 10.5 months
- Population
- US adults ≥18 years with type 2 diabetes starting tirzepatide or a GLP-1 RA, without baseline stage 5 CKD/kidney failure or recent MI/stroke
- Outcome
- All-cause mortality (primary); MACEs, kidney events, AKI, and major adverse kidney events
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
After median 10.5 months, 0.6% vs 1.1% died on tirzepatide vs GLP-1 RA (AHR 0.58). MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) were also lower, with greater HbA1c and weight drops.
Methodology
Used TriNetX records of adults initiating tirzepatide or a GLP-1 RA, excluded advanced kidney failure and recent stroke/MI, matched on 48 variables, and compared mortality, MACEs, and kidney outcomes with Cox models.
Limitations
Observational matching cannot prove tirzepatide causes fewer deaths; residual confounding, short follow-up, and US EHR coverage limit causal and global claims.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
In US EHR data, starting tirzepatide associated with fewer deaths and CV/kidney events than starting a GLP-1 RA.
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Evidence for the claim as stated.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as supporting evidence on GLP-1 receptor agonists
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Placed as supporting evidence on GLP-1 receptor agonists
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Related papers in this topic
Same topic cluster — not a recommendation engine.